Menu
← Oncology Approval Tracker
FDA DECISION ·
Jemperli
dostarlimab-gxly · GlaxoSmithKline
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with dMMR recurrent or advanced endometrial cancer by an FDA-approved test, after progression during or following a platinum-containing regimen.
LAMPGEN ANALYSIS
Why it matters
The initial accelerated approval targeted a mismatch repair-deficient population after platinum. FDA later granted traditional approval on February 9, 2023.
What research teams should watch
Retain MMR testing details and dates of platinum exposure and progression.
PRIMARY RECORDS